EU-CTR: Preparing for trial transition

The EU Clinical Trial Regulation 536/2014 became mandatory for all new interventional clinical trials phase I-V early this year, meaning the need to work under new rules driven by the aim of harmonization across the EEA, electronic submission, digitalization of clinical trials management and new rules applying transparency. As a result, there are changes and adaptations to conduct trials in the EU. 

Join Parexel’s regulatory experts in this webinar-on-demand, as they share Parexel’s experience of different aspects of working under the EU environment for clinical trials, analyze the impact of the new requirements, and describe learnings gained since the EU-CTR implementation.

Specific focus areas include:

  • Timelines and procedures 
  • Readiness check and impact of the transition of trials
  • Planning and resourcing
  • Lessons learned on transitions

Return to Insights Center

Related Insights


CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024


Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021


U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022


New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022